Evidence map›Paper›PMID 36139096›Full record

ArticleBiomolecules2022

INTERCEPT Pathogen Reduction in Platelet Concentrates, in Contrast to Gamma Irradiation, Induces the Formation of

Gerda C Leitner, Gerhard Hagn, Laura Niederstaetter, Andrea Bileck, Kerstin Plessl-Walder, Michaela Horvath, Vera Kolovratova, Andreas Tanzmann, Alexander Tolios, Werner Rabitsch and 2 more

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Increase of Phosphoprotein Expressions in Amotosalen/UVA-Treated Platelet Concentrates.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2024
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Gerda C LeitnerDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Gerhard HagnDepartment of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.ORCID 0000-0001-6782-4117
Laura NiederstaetterDepartment of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.
Andrea BileckDepartment of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-7053-8856
Kerstin Plessl-WalderDivision of Biomedical Science, University of Applied Sciences, FH Campus Wien, 1100 Vienna, Austria.
Michaela HorvathDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Vera KolovratovaDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Andreas TanzmannDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Alexander ToliosDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0001-9163-7127
Werner RabitschInternal Medicine 1, Stem Cell Transplantation Unit, Medical University of Vienna, 1090 Vienna, Austria.
Philipp WohlfarthInternal Medicine 1, Stem Cell Transplantation Unit, Medical University of Vienna, 1090 Vienna, Austria.
Christopher GernerDepartment of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-4964-0642
Medical University of Vienna · ATUniversity of Vienna · ATHochschule Campus Wien · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathogen inactivation techniques for blood products have been implemented to optimize clinically safe blood components supply. The INTERCEPT system uses amotosalen together with ultraviolet light wavelength A (UVA) irradiation. Irradiation-induced inactivation of nucleic acids may actually be accompanied by modifications of chemically reactive polyunsaturated fatty acids known to be important mediators of platelet functions. Thus, here, we investigated eicosanoids and the related fatty acids released upon treatment and during storage of platelet concentrates for 7 days, complemented by the analysis of functional and metabolic consequences of these treatments. Metabolic and functional issues like glucose consumption, lactate formation, platelet aggregation, and clot firmness hardly differed between the two treatment groups. In contrast to gamma irradiation, here, we demonstrated that INTERCEPT treatment immediately caused new formation of

Indexed as

Arachidonic AcidsNucleic Acids12-Hydroxy-5,8,10,14-eicosatetraenoic AcidArachidonate 12-LipoxygenaseArachidonic AcidBlood PlateletsGlucoseHydroxyeicosatetraenoic AcidsLactatesSulfhydryl Compounds12-Hydroxy-5,8,10,14-eicosatetraenoic AcidArachidonate 12-LipoxygenaseArachidonic AcidArachidonic AcidsGlucoseHydroxyeicosatetraenoic AcidsLactatesNucleic AcidsSulfhydryl Compoundseicosanoidshigh-resolution mass spectrometryliquid chromatographypathogen reductionplatelet concentratesplateletstrans-arachidonic acids

Identifiers

PMID36139096
PMCPMC9496540
OpenAlexW4296793660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.